KR20220148233A - 고활성 nk 세포의 처리 방법 - Google Patents

고활성 nk 세포의 처리 방법 Download PDF

Info

Publication number
KR20220148233A
KR20220148233A KR1020227033295A KR20227033295A KR20220148233A KR 20220148233 A KR20220148233 A KR 20220148233A KR 1020227033295 A KR1020227033295 A KR 1020227033295A KR 20227033295 A KR20227033295 A KR 20227033295A KR 20220148233 A KR20220148233 A KR 20220148233A
Authority
KR
South Korea
Prior art keywords
cells
highly active
thawing
hours
medium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227033295A
Other languages
English (en)
Korean (ko)
Inventor
유이 하라다
요시카즈 요네미츠
Original Assignee
가부시키가이샤 가이아바이오메디신
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 가부시키가이샤 가이아바이오메디신 filed Critical 가부시키가이샤 가이아바이오메디신
Publication of KR20220148233A publication Critical patent/KR20220148233A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A01N1/0221—
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/125—Freeze protecting agents, e.g. cryoprotectants or osmolarity regulators
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/16—Physical preservation processes
    • A01N1/162—Temperature processes, e.g. following predefined temperature changes over time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/04—Preserving or maintaining viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Environmental Sciences (AREA)
  • Dentistry (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
KR1020227033295A 2020-03-02 2021-03-02 고활성 nk 세포의 처리 방법 Pending KR20220148233A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2020-035297 2020-03-02
JP2020035297A JP7793284B2 (ja) 2020-03-02 2020-03-02 高活性ｎｋ細胞の処理方法
PCT/JP2021/007863 WO2021177279A1 (ja) 2020-03-02 2021-03-02 高活性ｎｋ細胞の処理方法

Publications (1)

Publication Number Publication Date
KR20220148233A true KR20220148233A (ko) 2022-11-04

Family

ID=77614337

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227033295A Pending KR20220148233A (ko) 2020-03-02 2021-03-02 고활성 nk 세포의 처리 방법

Country Status (8)

Country Link
US (1) US20230109717A1 (https=)
EP (1) EP4151717A4 (https=)
JP (2) JP7793284B2 (https=)
KR (1) KR20220148233A (https=)
CN (1) CN115279887A (https=)
AU (1) AU2021230860A1 (https=)
TW (1) TW202140770A (https=)
WO (1) WO2021177279A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240063899A (ko) * 2021-09-08 2024-05-10 가부시키가이샤 가이아바이오메디신 세포의 처리 방법
EP4582545A1 (en) 2022-08-30 2025-07-09 GAIA BioMedicine Inc. Monobody and nk cells
AU2024234571A1 (en) 2023-03-15 2025-09-25 Gaia Biomedicine Inc. Solution for suspending cells and use thereof
KR102940135B1 (ko) 2024-01-05 2026-03-16 인하대학교 산학협력단 고삼투 및 진동 자극에 노출된 배양보조세포를 통한 nk 세포의 효과적인 활성화 및 이의 용도
CN121294344A (zh) * 2024-06-20 2026-01-09 杭州百瑞竞康生物技术有限公司 Nk细胞无血清培养基

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002233356A (ja) 2000-12-04 2002-08-20 Human Tekku:Kk 細胞の保存液および該保存液を用いた細胞の保存方法
JP2006230396A (ja) 2004-10-12 2006-09-07 Nipro Corp 細胞保存液
WO2011021618A1 (ja) 2009-08-19 2011-02-24 タカラバイオ株式会社 細胞の保存方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX342995B (es) 2010-07-13 2016-10-21 Anthrogenesis Corp Métodos de generar células asesinas naturales.
EP2925861B1 (en) 2012-11-29 2018-09-05 Takara Bio Europe AB Improved methods for producing mammalian pluripotent stem cell-derived endodermal cells
WO2016122014A1 (ko) * 2015-01-27 2016-08-04 한국생명공학연구원 자연살해세포의 대량생산 방법 및 상기 방법으로 수득된 자연살해세포의 항암제로서의 용도
MY201637A (en) * 2015-10-15 2024-03-06 Celularity Inc Natural killer cells and ilc3 cells and uses thereof
WO2018017843A1 (en) * 2016-07-22 2018-01-25 Tissue Testing Technologies Llc Enhancement of cell cryopreservation with glycolipids
JP7398959B2 (ja) 2017-05-04 2023-12-15 メゾブラスト・インターナショナル・エスアーエールエル 向上した免疫抑制作用を有する間葉系前駆または幹細胞
JP6647240B2 (ja) 2017-05-12 2020-02-14 米満　吉和 高活性ｎｋ細胞、およびその利用
JP2019024418A (ja) 2017-07-31 2019-02-21 公立大学法人大阪府立大学 選択分離用培地
JP6543375B1 (ja) 2018-03-27 2019-07-10 株式会社ガイアバイオメディシン ケモカインレセプターと細胞接着分子を発現するｃｄ３陰性細胞の集団、およびその利用
CN114615886A (zh) * 2019-08-29 2022-06-10 得克萨斯大学体系董事会 细胞冷冻保存培养基

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002233356A (ja) 2000-12-04 2002-08-20 Human Tekku:Kk 細胞の保存液および該保存液を用いた細胞の保存方法
JP2006230396A (ja) 2004-10-12 2006-09-07 Nipro Corp 細胞保存液
WO2011021618A1 (ja) 2009-08-19 2011-02-24 タカラバイオ株式会社 細胞の保存方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Liu E, et al. N Engl J Med. 2020 ; 382 : 545-53

Also Published As

Publication number Publication date
JP2023126695A (ja) 2023-09-07
JP7793284B2 (ja) 2026-01-05
JP2021136883A (ja) 2021-09-16
TW202140770A (zh) 2021-11-01
WO2021177279A1 (ja) 2021-09-10
CN115279887A (zh) 2022-11-01
US20230109717A1 (en) 2023-04-13
EP4151717A1 (en) 2023-03-22
EP4151717A4 (en) 2024-04-17
AU2021230860A1 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
KR20220148233A (ko) 고활성 nk 세포의 처리 방법
Yuan et al. Cryopreservation of human mesenchymal stromal cells expressing TRAIL for human anti-cancer therapy
US11412730B2 (en) Method for the cryopreservation of cells for therapeutic purposes
EP3000876B1 (en) Method for preparing nk cells
US20230277599A1 (en) Methods of Preserving Mesenchymal Stem Cells
CN105324480A (zh) 含有海藻糖及葡聚糖的哺乳动物细胞移植用溶液
AU2009228141A1 (en) Mehtod, system, and apparatus for hypothermic collection, storage, transport and banking of birth tissue
JP5840876B2 (ja) Ｎｋ細胞を増幅するための組成物及び方法
KR20180114073A (ko) 향상된 성체 간 전구 세포 제제
JP2022501322A (ja) 機能的な間葉系幹細胞の富化集団を得る方法、それによって得られる細胞、およびその細胞を含む組成物
Luo et al. The state of T cells before cryopreservation: Effects on post-thaw proliferation and function
Deng et al. Overexpressing cellular repressor of E1A-stimulated genes protects mesenchymal stem cells against hypoxia-and serum deprivation-induced apoptosis by activation of PI3K/Akt
Moldenhauer et al. Interleukin-3 greatly expands non-adherent endothelial forming cells with pro-angiogenic properties
Buchanan et al. Cryopreservation of human hematopoietic stem and progenitor cells loaded with trehalose: transient permeabilization via the adenosine triphosphate-dependent P2Z receptor channel
JP2024519222A (ja) ＮＫ細胞の凍結保存用組成物及びこれを含む凍結保存剤形｛ＮＫ ｃｅｌｌ ｃｒｙｏｐｒｅｓｅｒｖａｔｉｏｎ ｃｏｍｐｏｓｉｔｉｏｎ ａｎｄ ｃｒｙｏｐｒｅｓｅｒｖａｔｉｏｎ ｆｏｒｍｕｌａｔｉｏｎ ｃｏｍｐｒｉｓｉｎｇ ｔｈｅ ｓａｍｅ｝
US20240366673A1 (en) Method for treating cells
EP4682242A1 (en) Solution for suspending cells, and use of same
HK40084673A (en) Method for treating highly active nk cells
HK40083554A (en) Method for treating highly active nk cells
Kozlowska-Skrzypczak et al. Analysis of the effect of cryoprotectant medium composition to viability of autologous hematopoietic cells collected by leukapheresis
HK40108875A (en) Method for treating cells
JP2025146940A (ja) 拡大した幹細胞生成物を使用して、血液悪性腫瘍を有する患者の処置転帰を改善するための組成物および方法
Davidson Microvesicles and exosomes in local and distant communication with the heart
McFarland et al. ASH 2010 meeting report—Top 10 clinically oriented abstracts in transfusion medicine

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902